Loading…
Chinese maker of disposable medical devices and consumables, including orthopedic implants, syringes and infusion products.
Chinese maker of disposable medical devices and consumables, including orthopedic implants, syringes and infusion products.
Sells disposable consumables through distributors and hospital tenders, a business of high volumes and steady repeat use. China's volume-based procurement, national bulk tenders in which the lowest bids win large orders, has pushed down prices on implants and other devices, so winning tenders matters.
In one line: China's answer to a diversified Becton Dickinson/Medtronic-lite medical device maker.
Moat: narrow (scale, regulatory licence, distribution). Broad product registrations and a large domestic distribution network across China's hospital system.
Headquarters: Weihai, Shandong, China · Founded: 1988 · Employees: 13,307
Size Shandong Weigao Group Medical Polymer (1066.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $1.96B, the 422nd largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$3.40 on 6 Nov 2026.
Performance Over six months the shares fell 4.3%, against -4.3% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue grew 7.5% over the last twelve months (peer median +11.6%); the operating margin is 13.6% (peer median 10.9%).
Valuation It trades at 8.8× forward earnings against a peer median of 39.7× (2nd cheapest of 19).
Price implies For today's price to make sense, revenue must grow about -12% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -14 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.3 points below its cost of capital (6.6% WACC).
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$15.2B | HK$14.5B | HK$14.2B | HK$14.6B | HK$16.0B |
| Revenue growth | — | +2% | -3% | -9% | — |
| Gross profit | HK$6.67B | HK$6.60B | HK$6.82B | HK$7.04B | HK$8.20B |
| EBITDA | HK$3.20B | HK$3.10B | HK$3.59B | HK$3.50B | HK$4.56B |
| Net income | HK$1.54B | HK$1.75B | HK$2.24B | HK$2.21B | HK$3.21B |
| Free cash flow | n/a | HK$1.99B | HK$2.17B | HK$2.04B | HK$1.42B |
| Capital expenditure | n/a | HK$903M | HK$702M | HK$758M | HK$1.30B |
| Total debt | n/a | HK$6.59B | HK$5.45B | HK$5.26B | HK$5.36B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shandong Weigao Group Medical Polymer 1066.HK | $1.96B | -4% | +7% | 14% | 8.8× | -11.8% |
| Becton Dickinson BDX | $57.7B | +43% | -3% | 15% | 16.0× | 9.6% |
| Medtronic MDT | $130B | +35% | +10% | 20% | 16.9× | 8.6% |
| MicroPort Scientific 0853.HK | n/a | -45% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1066.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.8% | -0.5% | 8th highest of 21 |
| 6-month return | -4.3% | -4.3% | 11th highest of 21 |
| Distance from 52-week high | -41.5% | -24.7% | 6th lowest of 21 |
| Revenue growth (TTM) | +7.5% | +11.6% | 8th lowest of 21 |
| Operating margin | 13.6% | 10.9% | 9th highest of 21 |
| Forward P/E | 8.8× | 39.7× | 2nd cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | -11.8% | 12.9% | 2nd least demanding of 15 |
| Growth delivered (Del g) | +2.1% | +12.3% | 4th lowest of 15 |
| Hurdle (Req g minus delivered) | -14.0 pp | -7.8 pp | 4th least demanding of 15 |
| ROIC minus cost of capital | -0.3 pp | +0.2 pp | 11th highest of 21 |
| EV / EBITDA | 4.0× | 18.8× | cheapest of 12 |
| Net debt / EBITDA | -1.5× | -0.9× | 5th least indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shandong Weigao Group Medical Polymer 1066.HK | Hong Kong | $1.96B | -4% | +7% | 14% | 8.8× | -11.8% | +2.1% |
| JEOL 6951.T | Japan | $1.98B | -3% | -18% | 11% | 14.2× | 21.3% | +10.2% |
| Mehow Innovative 301363.SZ | China | $1.95B | -14% | +10% | 21% | 38.8× | 18.9% | +12.9% |
| Veracyte VCYT | United States | $1.94B | -40% | +17% | 17% | 14.9× | 15.1% | +34.5% |
| Establishment Labs ESTA | United States | $2.00B | -7% | +38% | -7% | n/a | n/a | n/a |
| SKAN SKAN.SW | Switzerland | $1.92B | +49% | +9% | 11% | 49.8× | 13.8% | +11.7% |
| Draegerwerk AG & Co. KGaA DRW8.DE | Germany | $1.89B | +17% | +5% | 7% | 9.4× | -12.6% | +0.4% |
| DENTSPLY SIRONA XRAY | United States | $1.89B | -14% | -1% | 5% | 7.3× | 10.2% | +1.9% |
| Inspire Medical Systems INSP | United States | $1.85B | +45% | 0% | 2% | 45.4× | 30.9% | +51.2% |
| LeMaitre Vascular LMAT | United States | $1.85B | -25% | +12% | 29% | 26.2× | 2.9% | +14.0% |
| Inner Mongolia Furui Medical Science 300049.SZ | China | $1.85B | -5% | +11% | 25% | 53.2× | 6.6% | +14.6% |
| Medartis MED.SW | Switzerland | $1.83B | +47% | +30% | 2% | 74.2× | n/a | n/a |
| Wuxi Unicomp Technology 688531.SS | China | $1.80B | -36% | +53% | 12% | 40.7× | n/a | n/a |
| Bonesupport BONEX.ST | Sweden | $2.16B | +34% | +25% | 25% | 61.9× | 13.3% | +45.4% |
| Fukuda Denshi 6960.T | Japan | $1.75B | -5% | 0% | 19% | 14.6× | -3.2% | -1.0% |
| Embla Medical hf EMBLA.CO | Denmark | $1.75B | +3% | +6% | 14% | 17.9× | -1.8% | +8.3% |
| Angelalign Technology 6699.HK | Hong Kong | $1.74B | -7% | +84% | 9% | 52.1× | 18.1% | +25.8% |
| Poly Medicure POLYMED.NS | India | $1.73B | -4% | +18% | 17% | 40.6× | n/a | n/a |
| Kestra Medical Technologies KMTS | United States | $1.72B | +37% | +61% | -134% | n/a | n/a | n/a |
| Metall Zug METN.SW | Switzerland | $2.25B | +19% | 0% | -10% | 139.2× | n/a | n/a |
| Cofoe Medical Technology 301087.SZ | China | $1.71B | -5% | +33% | 10% | 26.9× | 12.5% | +7.4% |